glycosylphosphatidylinositol

E1210 (APX001A) is broad-spectrum and orally active antifungal

APX2039 is an orally active fungal Gwt1 enzyme inhibitor and a prodrug of the novel Gwt2096 inhibitor APX1.APX2039 exhibits potent anti-Kryptococcal activity against C. neoformans and C. gattii.APX2039 exhibits potent antifungal activity and blocks the localization of GPI (glycosylphosphatidylinositol) anchored cell wall mannoproteins. APX2039 has potent antifungal activity and blocks the localization of GPI (glycosylphosphatidylinositol)-anchored cell wall mannoproteins.APX2039 can be used to study cryptococcal meningitis (CM).

D-chiro-Inositol (D-(+)-CHIRO-INOSITOL) is an epimer of myo-inositol that is found in certain mammalian glycosylphosphatidylinositol protein anchors and inositol phosphoglycans possessing insulin-like bioactivity.

Aminopyrifen is a fungicide that inhibits GWT-1 protein in glycosylphosphatidylinositol-anchor biosynthesis in Neurospora crassa.

Anti-FOLR1/FRA Antibody is a humanized monoclonal antibody targeting Folate Receptor alpha (FOLR1/FRA/FRα). FOLR1 is a Glycosylphosphatidylinositol (GPI)-anchored membrane protein responsible for mediating high-affinity folate uptake into cells. It is significantly overexpressed in various epithelial cancers, including ovarian, breast, and lung cancers, while showing restricted expression in normal tissues (except the kidney proximal tubules), making it an ideal tumor target. Anti-FOLR1/FRA Antibody specifically binds to FOLR1 on the tumor cell surface, blocking Lyn kinase-mediated signaling to inhibit cell proliferation, and inducing potent Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC) to directly kill tumor cells. Furthermore, as the targeting moiety of Antibody-Drug Conjugates (ADCs), it serves as a critical vehicle for delivering cytotoxic payloads (e.g., DM4) into tumor cells.

Anti-Mesothelin Antibody (such as Amatuximab/MORAb-009) is a chimeric monoclonal antibody targeting mesothelin (MSLN). Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that is overexpressed in various malignancies, including mesothelioma, pancreatic cancer, and ovarian cancer, while exhibiting restricted expression in normal tissues. The antibody binds to mesothelin with high affinity, and its mechanisms of action primarily include: 1. Blocking the interaction between mesothelin and MUC16 (CA125), thereby inhibiting tumor cell adhesion and metastasis; 2. Inducing direct tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC). In basic research, it is widely utilized to evaluate the therapeutic efficacy of targeting mesothelin and for the development of antibody-drug conjugates (ADCs).